Jefferies downgraded Gerresheimer AG to 'Hold' from 'Buy' on May 19, 2026.
The firm reduced its price target to €26.80 from €34.10.
Growing concerns over execution risks from the recent Bormioli Pharma acquisition drove the downgrade. Jefferies expects slower and more costly synergy realization than initially anticipated.
Repeated delays in publishing financial results lowered investor confidence. Gerresheimer AG also faces management uncertainty.